DCI - Mccrory is a medicare approved dialysis facility center in Mccrory, Arkansas and it has 9 dialysis stations. It is located in Woodruff county at 139 W Hwy 64 Ste 100, Mccrory, AR, 72101. You can reach out to the office of DCI - Mccrory at (870) 731-0220. This dialysis clinic is managed and/or owned by Dialysis Clinic, Inc.. DCI - Mccrory has the following ownership type - Non-Profit. It was first certified by medicare in September, 2008. The medicare id for this facility is 042583 and it accepts patients under medicare ESRD program.
| Name | DCI - Mccrory |
|---|---|
| Location | 139 W Hwy 64 Ste 100, Mccrory, Arkansas |
| No. of Dialysis Stations | 9 |
| Medicare ID | 042583 |
| Managed By | Dialysis Clinic, Inc. |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 139 W Hwy 64 Ste 100, Mccrory, Arkansas, 72101 | |
| (870) 731-0220 | |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
| NPI Number | 1881854396 |
| Doing Business As | Dialysis Clinic Inc. |
| Address | 139 W Highway 64 Mc Crory, Arkansas, 72101 |
| Phone Number | (870) 731-0220 |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 14 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 7 |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 19 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 184 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
| Adult patients getting regular peritoneal dialysis at the center | 2 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 14 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at DCI - Mccrory with elevated calcium levels.
| Patients with hypercalcemia | 21 |
| Hypercalcemia patient months | 209 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 3 |
| Patients with Serumphosphor | 23 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 19 |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 19 |
| Patient months included in arterial venous fistula and catheter summaries | 168 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 82 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 19 |
| Hospitalization Rate in facility | 58.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 241.8 |
| Hospitalization Rate: Lower Confidence Limit | 15.8 |
News Archive
Advaita Corporation, a startup company based on technology developed at Wayne State University by Sorin Draghici, Ph.D., professor of computer science in the College of Engineering, received the final installment of a $125,000 award from the Michigan Emerging Technologies Fund program.
A survey of 305 students at one campus found that 40 percent of cell phone users said they walked somewhere after dark that they normally wouldn't go.
Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.
Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.
Clarient, Inc. announced today the extension of the current pending offer by Crane Merger Sub, Inc., an indirect wholly-owned subsidiary of General Electric Company to acquire all of the outstanding shares of capital stock of the Company.
› Verified 6 days ago